A 6-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy and Safety Study of SYMBICORT pMDI 2 x 160/4.5 microg and 80/4.5 microg Bid Compared to Formoterol TBH, Budesonide pMDI (and the Combination) and Placebo in COPD Patients.

Trial Profile

A 6-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy and Safety Study of SYMBICORT pMDI 2 x 160/4.5 microg and 80/4.5 microg Bid Compared to Formoterol TBH, Budesonide pMDI (and the Combination) and Placebo in COPD Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Sep 2014

At a glance

  • Drugs Budesonide; Budesonide/formoterol; Formoterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms SHINE
  • Sponsors AstraZeneca
  • Most Recent Events

    • 18 May 2011 Results presented at the 107th International Conference of the American Thoracic Society.
    • 20 May 2009 Symptom exacerbation results reported at the 105th International Conference of the American Thoracic Society.
    • 20 May 2009 Results on symptoms reported at the 105th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top